EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants

Edward Pratt iD, Xiaosu Ma, Rong Liu, Deborah Robins, Axel Haupt iD, Tamer Coskun iD, Kyle W Sloop, Charles Benson

Diabetes, Obesity and Metabolism · 2023-09 · 25 (9) · 2634-2641

DOI: 10.1111/dom.15184 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 21.06.2023. Verfasst von Edward Pratt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Centre for Clinical Pharmacology Pte Ltd, Singapore. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of orforglipron (LY3502970), an oral, non‐peptide glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) in healthy participants. Materials and Methods This was a double‐blind, placebo‐controlled, Phase 1 study. Overtly healthy adults aged 18 to 65 years with body mass index of 20 to 40 kg/m 2 and glycated haemoglobin concentration of 47.5 mmol/mol (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsDiabetes Mellitus, Type 2AdultHumansGlucagon-Like Peptide-1 ReceptorHealthy VolunteersBlood GlucoseDouble-Blind Method

Stichwörter der Autor:innen

GLP-1antidiabetic drugpharmacodynamicspharmacokineticsphase I-II studyweight control

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorBlood Glucose

Autor:innen und Institutionen

  • Lilly Centre for Clinical Pharmacology Pte Ltd, Singapore.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Edward Pratt, Axel Haupt, Tamer Coskun

Förderung

  • Eli Lilly and Company

Zitieren

APA

Pratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T., Sloop, K. W., & Benson, C. (2023). Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants. Diabetes, Obesity and Metabolism, 25(9), 2634-2641. https://doi.org/10.1111/dom.15184

Vancouver

Pratt E, Ma X, Liu R, Robins D, Haupt A, Coskun T, et al. Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants. Diabetes, Obesity and Metabolism. 2023;25(9):2634-2641. doi:10.1111/dom.15184

BibTeX
@article{Pratt2023,
  author = {Pratt, Edward and Ma, Xiaosu and Liu, Rong and Robins, Deborah and Haupt, Axel and Coskun, Tamer and Sloop, Kyle W and Benson, Charles},
  title = {Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  volume = {25},
  number = {9},
  pages = {2634--2641},
  doi = {10.1111/dom.15184}
}
Kostenlos starten →